Long-term survival in patients with refractory angina

European Heart Journal

Volumn 34, Issue 34, 2013, Pages 2683-2688

  Henry, Timothy D ^a,b   Satran, Daniel ^a,b,c   Hodges, James S ^a,b   Johnson, Randall K ^a   Poulose, Anil K ^a   Campbell, Alex R ^a   Garberich, Ross F ^a   Bart, Bradley A ^b,d   Olson, Rachel E ^a   Boisjolie, Charlene R ^a   Harvey, Karen L ^a   Arndt, Theresa L ^a   Traverse, Jay H ^a,b  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Park Nicollet Heart and Vascular Center   (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Chronic coronary artery disease; Refractory angina

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CLINICAL STUDY; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEATH; DEATH CERTIFICATE; DIABETES MELLITUS; DISEASE SEVERITY; EXPERIMENTAL THERAPY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

CHRONIC CORONARY ARTERY DISEASE; REFRACTORY ANGINA;

ADULT; AGED; ANGINA PECTORIS; CAUSE OF DEATH; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MINNESOTA; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84890096338     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht165     Document Type: Article

References (45)

1. Mannheimer C, Camici P, Chester MR, Collins A, DeJongste M, Eliasson T, Follath F, Hellemans I, Herlitz J, Lüscher T, Pasic M, Thelle D. The problem of chronic refractory angina: Report from the European Society of Cardiology joint study grouponthe treatment of refractory angina. Eur Heart J 2002;23:355-370
2. Jolicoeur EM, Granger CB, Henry TD, Holmes DJ, Pepine CJ, Mark D, Chaitman BR, Gersh BJ, Ohman EM, Working Group Members. Clinical and research issues regarding chronic advanced coronary artery disease part I: Contemporary and emerging strategies. Am Heart J 2008;155:418-434
3. Jolicoeur EM, Ohman EM, Temple R, Stockbridge N, Smith S, Mark D, Califf RM, Henry TD, Chaitman BR, Granger CB, Working Group Members. Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues. Am Heart J 2008;155:435-444
4. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER, VIVA Investigators. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003;107:1359-1365
5. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation 2002;105: 788-793
6. Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, RuzylloW, Bøtker HE, Dudek D, Drvota V, Hesse B, Thuesen L, Blomberg P, GyöngyösiM, Sylvén C, Euroinject One Group. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: A randomized doubleblind placebo-controlled study: The Euroinject One trial. J Am Coll Cardiol 2005; 45:982-988
7. Henry TD, Grines CL, WatkinsMW, Dib N, Barbeau G, Moreadith R, Andrasfay T, Engler RL. Effects of Ad5FGF-4 in patients with angina: An analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 2007;50:1038-1046
8. Losordo DW, Henry TD, Davidson C, Lee JS, Costa M, Mendelsohn F, Fortuin D, Pepine C, Traverse J, Amrani D, Ewenstein BM, Riedel N, Story K, Povsic T, Harrington RA, Schatz RA, for the ACT34-CMI Investigators. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res 2011;109:428-436
9. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L, ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) Trial. J Am Coll Cardiol 2006;48: 566-575
10. Arora RR, Chou TM, Jain D, Fleishman B, Crawford L, McKiernan T, NestoRW. The multicenter study of enhanced external counterpulsation (MUST-EECP): Effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol 1999;33:1833-1840
11. Michaels AD, McCullough PA, Soran OZ, Lawson WE, Barsness GW, Henry TD, Linnemeier G, Ochoa A, Kelsey SF, Kennard ED. Primer: Practical approach to the selection of patients for and application of EECP. Nat Clin Pract Cardiovasc Med 2006;3:623-632
12. Manchanda A, Soran O. Enhanced external counterpulsation and future directions: Step beyond medical management for patients with angina and heart failure. J AmColl Cardiol 2007;50:1523-1531
13. Mannheimer C, Eliasson T, Augustinsson LE, Blomstrand C, Emanuelsson H, Larsson S, Norrsell H, Hjalmarsson A. Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: The ESBY study. Circulation 1998; 97:1157-1163
14. Allen KB, Dowling RD, Fudge TL, Schoettle GP, Selinger SL, Gangahar DM, AngellWW, Petracek MR, Shaar CJ, O'NeillWW. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med 1999;341:1029-1036
15. Frazier OH, March RJ, Horvath KA. The transmyocardial carbon dioxide laser revascularization study group. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med 1999;341: 1021-1028
16. Burkhoff D, Schmidt S, Schulman SP, Myers J, Resar J, Becker LC, Weiss J, Jones JW. Transmyocardial laser revascularization compared with continued medical therapy for treatment of refractory angina pectoris: A prospective randomised trial. Lancet 1999;354:885-890
17. Schofield PM, Sharples LD, Caine N, Burns S, Tait S, Wistow T, Buxton M, Wallwork J. Transmyocardial laser revascularization in patients with refractory angina: A randomised controlled trial. Lancet 1999;353:519-524
18. Leon MB, Kornowski R, Downey WE, Weisz G, Baim DS, Bonow RO, Hendel RC, Cohen DJ, Gervino E, Laham R, Lembo NJ, Moses JW, Kuntz RE. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol 2005;46:1812-1819
19. Aaberge L, Nordstrand K, Dragsund M, Saatvedt K, Endresen K, Golf S, Geiran O, Abdelnoor M, Forfang K. Transmyocardial revascularization with CO2 laser in patients with refractory angina pectoris: Clinical results from the Norwegian randomized trial. J Am Coll Cardiol 2000;35:1170-1177
20. Mukherjee D, Comella K, Bhatt DL, Roe MT, Patel V, Ellis SG. Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization. Am Heart J 2001;142:72-74
21. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, Gibbons RJ, Alpert JS, Antman EM, Hiratzka LF, Fuster V, Faxon DP, Gregoratos G, Jacobs AK, Smith SC Jr, American College of Cardiology; American Heart Association Task Force on Practice Guidelines. Committee on the Management of Patients With Chronic Stable Angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: A report of the American College of Cardiology/ American Heart Association task force on practice guidelines (committee to update the 1999 guidelines for the management of patients with chronic stable angina). Circulation 2003;107:149-158
22. Boyle CA, Decoufle P. National sources of vital status information: Extent of coverage and possible selectivity in reporting. Am J Epidemiol 1990;131:160-168
23. Curb JD, Ford CE, Pressel S, Palmer M, Babcock C, Hawkins CM. Ascertainment of vital statistics through the National Death Index and Social Security Administration. Am J Epidemiol 1985;121:754-766
24. International Classification of Diseases, Ninth Revision (ICD-9). Geneva, Switzerland: World Health Organization; 1977
25. International Statistical Classification of Diseases, 10th Revision (ICD-10). Geneva, Switzerland: World Health Organization; 1992
26. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-e151
27. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes DR Jr, Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013;381:629-638
28. Bernstein SJ, Brorsson B, Aberg T, Emanuelsson H, Brook RH, Werko L. Appropriateness of referral of coronary angiography patients in Sweden.SECOR/SBU Project Group. Heart 1999;81:470-477
29. Brorsson B, Bernstein SJ, Brook RH, Werko L. Quality of life of patients with chronic stable angina before and four years after coronary revascularization compared with a normal population. Heart 2002;87:140-145
30. Mukherjee D, Bhatt DL, Roe MT, Patel V, Ellis SG. Direct myocardial revascularization and angiogenesis-how many patients might be eligible? Am J Cardiol 1999; 84:598-600.
31. Williams B, Menon M, Satran D, Hayward D, Hodges JS, Burke MN, Johnson RK, Poulose AK, Traverse JH, Henry TD. Patients with coronary artery disease not amenable to traditional revascularization: Prevalence and 3-year mortality. Catheter Cardiovasc Interv 2010;75:886-891
32. Lenzen MJ, Boersma E, Bertrand ME, Maier W, Moris C, Piscione F, Sechtem U, Stahle E, Widimsky P, de Jaegere P, Scholteop Reimer WJ, Mercado N, Wijns W, European Society of Cardiology. Management and outcome of patients with established coronary artery disease: The Euro Heart surveyon coronary revascularization. Eur Heart J 2005;26:1169-1179
33. Lenzen MJ, Reimer WS, Norekval TM, De Geest S, Fridlund B, Heikkila J, Jaarsma T, Martensson J, Moons P, Smith K, Stewart S, Strömberg A, Thompson DR, WijnsW. Pharmacological treatment and perceived health status during 1-year follow up in patients diagnosed with coronary artery disease, but ineligible for revascularization: Results from the Euro Heart Survey on coronary revascularization. Eur J Cardiovasc Nur 2006;5:115-121
34. Kandzari DE, Lam LC, Eisenstein EL, Clapp-Channing N, Fine JT, Califf RM, Mark DB, Jollis JG. Advanced coronary artery disease: Appropriate end points for trials of novel therapies. Am Heart J 2001;142:843-851
35. Loh PH, Cleland JGF, Louis AA, Kennard ED, Cook JF, Caplin JL, Barsness GW, Lawson WE, Soran OZ, Michaels AD. Enhanced external counterpulsation in the treatment of chronic refractory angina: A long-Term follow-up outcome from the international enhanced external counterpulsation patient registry. Clin Cardiol 2008;31:159-164
36. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina: A randomized, placebo-controlled clinical trial. Ann Int Med 1991;114:835-839
37. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153
38. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-732
39. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-990
40. Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, Wang CH, Heiss G. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998;339:861-867
41. Setoguchi S, Glynn RJ, Avorn J, Mittleman MA, Levin R, Winkelmayer WC. Improvements in long-Term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: A 10-year trend analysis. J Am Coll Cardiol 2008; 51:1247-1254
42. Pennell DJ. Perfusion abnormality, normal coronaries, and chest pain. J AmColl Cardiol 2008;51:473-475
43. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl Med 2007; 356:830-840
44. Kornowski R. Refractory myocardial angina and determinants of prognosis. Catheter Cardiovasc Interv 2010;75:892-894
45. Jolicoeur EM, Cartier R, Henry TD, Barsness GW, Bourassa MG, McGillion M, L'Allier PL. Patients with coronary refractory artery disease unsuitable for revascularization: Definition, general principles and a classification. Can J Cardiol 2012; 28(Suppl. A):S50-S59